Quick Takeaways: Why It Matters? Cronus Pharma’s launch of Florfinasone Otic (florfenicol + terbinafine + mometasone) adds an FDA‑approved, single‑use, triple‑action topical for canine otitis externa to a growing companion‑animal ear‑infection market. The fixed‑dose combination...
Quick Takeaways: Why It Matters? Cronus Pharma’s launch of Robenacoxib Injection gives US veterinarians the first FDA‑approved bioequivalent to Onsior (robenacoxib) Injection, providing a cost‑effective, short‑term NSAID option for postoperative pain an...
Quick Takeaways: Why It Matters? Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors. For the market, this should lo...
